Tamara Dušan Filipović

Dr. Tamara Dušan Filipović

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2026 in Acta Cardiologica
Verified
Journal Article
Closed access
MBMiodrag Belopavlović
Miodrag Belopavlović
MRMilan Rodić
Milan Rodić
NSNikola Stipić
Nikola Stipić
Andrej PrevedenAndrej Preveden
Andrej Preveden
AMAleksandra Milovancev
Aleksandra Milovancev
Lazar VelickiLazar Velicki
Lazar Velicki
Heart failure (HF) is a major global health issue with significant morbidity, mortality, and economic burden. Differentiating between heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) is essential for diagnosis, prognosis, and treatment. The aim of this study was to evaluate and compare the clinical, laboratory, and echocardiographic characteristics of patients with HFrEF and HFpEF. This retrospective, multicentre study included 2156 patients diagnosed with HF between 2003 and 2023 across four Serbian medical institutions. Patients were classified into HFrEF (LVEF <40%) or HFpEF (LVEF ≥50%) groups. Patients with mid-range ejection fraction (HFmrEF) were excluded. Clinical symptoms, comorbidities, laboratory findings, and echocardiographic data were analysed and compared between groups. Compared to the patients with HFrEF, those with HFpEF were older (73.5 vs. 69.5 years, p < 0.001) and more often female (56.6% vs. 26.0%, p < 0.001). HFpEF patients had higher rates of hypertension, atrial fibrillation, and obesity, while HFrEF patients more frequently had prior myocardial infarction and valvular disease. NT-proBNP, troponin, and CRP levels were significantly higher in HFrEF. Echocardiography showed greater left ventricular dilation and dysfunction in HFrEF, while HFpEF patients had preserved systolic but impaired diastolic function. Significant differences in demographic, clinical, and diagnostic profiles exist between HFrEF and HFpEF patients. Understanding these distinctions may enhance early recognition, risk stratification, and tailored therapeutic strategies for each phenotype.

22 June 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SDSonja Dakić
Sonja Dakić
ZPZoran Perišić
Zoran Perišić
SASvetlana Apostolovic
Svetlana Apostolovic
TKTomislav Kostić
Tomislav Kostić
GKGoran Koraćević
Goran Koraćević
TFTamara Dušan Filipović
Tamara Dušan Filipović
Background and Objectives: Ticagrelor reduces ischemic events in acute coronary syndrome (ACS) but increases bleeding risk. Clinical predictors of bleeding are well established; the contribution of cytochrome P450 polymorphisms involved in ticagrelor metabolism remains uncertain, with conflicting reports in the literature. We examined the association of CYP3A4* 22 (rs 35599367), CYP3A5* 3 (rs 776746), and CYP4F2 (rs3093135) with bleeding in a Serbian ACS cohort. Materials and Methods: This prospective, single- center observational study enrolled 105 consecutive ACS patients undergoing percutaneous coronary intervention (PCI) or medical management after coronary angiography and receiving dual antiplatelet therapy (DAPT) with acetylsalicylic acid and ticagrelor at the University Clinical Center Niš between January 2024 and the end of May 2025. Bleeding events occurring during the index hospitalization and the six-month follow-up were classified according to the Bleeding Academic Research Consortium (BARC) criteria. Genotyping used TaqMan assays. Associations with bleeding were assessed using Firth’s penalized logistic regression, with multivariable adjustment for age and renal function. Severity-stratified analyses and gradient-boosted machine learning (XGBoost with SHAP) were performed as exploratory analyses. Results: Thirteen patients (12.4%) experienced bleeding (nine minor [BARC 1/2], four major [BARC 3/5]). Age ≥ 75 years (univariable OR 7.62, p = 0.001) and eGFR < 60 mL/min/1. 73 m 2 (OR 3.68, p = 0.006) were the strongest predictors. CYP3A5 *1 carrier status was univariably associated with bleeding (OR 4.16, p = 0.043) but did not remain significant after adjustment for age and renal function, and *1 carriers were significantly older and more likely to have impaired renal function. No genotype was associated with major (BARC 3/5) bleeding. The apparent effect was concentrated in minor bleeding (BARC 1/2 rate: 30.8% versus 5.5%), with no major events among *1 carriers. CYP 3 A 4* 22 (OR 1.37, p = 0.109) and CYP 4 F 2 (OR 1.17, p = 0.111) showed no association. Machine-learning analyses confirmed eGFR and age as the dominant predictors. Conclusions: In this Serbian ACS cohort, clinical factors—particularly advanced age and impaired renal function—dominated the prediction of bleeding risk. The CYP3A5 signal was largely explained by baseline imbalances in age and renal function. CYP 3 A 4* 22 and CYP 4 F 2 polymorphisms did not contribute additional predictive information. Preemptive genotyping for these variants is unlikely to materially improve bleeding-risk assessment beyond standard clinical evaluation in patients of this type.